Evidence Library
Filter by drug, type, year, and open access.
Showing 1–50 of 427 results
- Autonomic dysfunctions in psychotic disorders, interaction with antipsychotic intervention and treatment resistance: a comprehensive systematic review and meta-analysis — Journal of Psychiatric Research (2026)• Drug: clozapinePMID
- Efficacy of combined nicotine replacement therapy (NRT) and bupropion compared to bupropion alone for smoking cessation: a systematic review and meta-analysis — Addictive Behaviors (2026)• Drug: bupropionPMID
- Effect of adding cognitive behavioral therapy to quetiapine on suicide risk, depressive symptoms, and coping style in adult patients with mood disorders — Journal of Psychiatric Research (2026)• Drug: quetiapinePMID
- Prevalence of dermatologic side effects of mood stabilizers in bipolar disorder: A systematic review and meta-analysis — Journal of Psychiatric Research (2026)• Drug: carbamazepinePMID
- Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with Schizophrenia — CNS Drugs (2026)• Drug: risperidone-uzedyPMID
- The effect of switching antipsychotics to aripiprazole versus paliperidone on weight/cardiometabolic parameters: 18-month follow-up findings from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST) — European Neuropsychopharmacology (2026)• Drug: aripiprazolePMID
- Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis — Journal of Affective Disorders (2026)• Drug: ketaminePMID
- Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: a systematic review of treatment protocols and clinical outcomes — Journal of Affective Disorders (2026)• Drug: ketaminePMID
- The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review — Journal of Psychiatric Research (2026)• Drug: ketaminePMID
- Prevalence of dermatologic side effects of mood stabilizers in bipolar disorder: A systematic review and meta-analysis — Journal of Psychiatric Research (2026)• Drug: lithiumPMID
- Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial — JAMA Psychiatry (2026)• Drug: semaglutide-ozempicPMID
- Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial — JAMA Psychiatry (2026)• Drug: semaglutide-wegovyPMID
- Transdiagnostic effectiveness and safety of clozapine in individuals with psychotic, affective, and personality disorders: nationwide and meta-analytic comparisons with other antipsychotics — The Lancet Psychiatry (2025)• Drug: clozapinePMID
- Brexpiprazole for the treatment of co-occurring schizophrenia and substance use disorder: a multisite, randomized, controlled trial — Journal of Clinical Psychiatry (2025)• Drug: brexpiprazolePMID
- Antipsychotic-related prolactin changes: a systematic review and dose-response meta-analysis — CNS Drugs (2025)• Drug: brexpiprazolePMID
- Strategies for switching between oral postsynaptic antidopaminergic antipsychotics in patients with schizophrenia: a systematic review — CNS Drugs (2025)• Drug: brexpiprazolePMID
- Efficacy and Tolerability of Bupropion in Major Depressive Disorder with Comorbid Anxiety Symptoms: A Systematic Review — International Journal of Molecular Sciences (2025)• Drug: bupropionPMID
- Does Adjuvant Metformin Reduce Olanzapine-Induced Metabolic Adverse Effects in Patients Diagnosed With Schizophrenia — Neuropsychopharmacology Reports (2025)• Drug: olanzapinePMID
- Antipsychotic-related prolactin changes: a systematic review and dose-response meta-analysis — CNS Drugs (2025)• Drug: quetiapinePMID
- Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial — BMC Psychiatry (2025)• Drug: risperidoneOpen accessPMID
- Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose-response meta-analysis — Translational Psychiatry (2025)• Drug: levomilnacipranPMID
- The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis — The Lancet (2025)• Drug: levomilnacipranPMID
- Effect of antidepressants on ejaculation dysfunction in patients with depression and anxiety: a systematic review and network meta-analysis — Andrology (2025)• Drug: levomilnacipranPMID
- Levomilnacipran, but not duloxetine, inhibits serotonin and norepinephrine reuptake throughout its therapeutic range — Journal of Clinical Psychiatry (2025)• Drug: levomilnacipranPMID
- A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorder — Psychiatry and Clinical Neurosciences (2025)• Drug: venlafaxinePMID
- Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial — Journal of Clinical Psychiatry (2025)• Drug: lumateperonePMID
- Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial — American Journal of Psychiatry (2025)• Drug: lumateperonePMID
- Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD) — Journal of Affective Disorders (2025)• Drug: duloxetinePMID
- Fixed-Dose Brexpiprazole and Sertraline Combination Therapy for the Treatment of Posttraumatic Stress Disorder: A Phase 3, Randomized Trial — Journal of Clinical Psychopharmacology (2025)• Drug: sertralinePMID
- Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses — Molecular Psychiatry (2025)• Drug: fluoxetinePMID
- Consistent differential effects of bupropion and mirtazapine in major depression — Journal of Affective Disorders (2025)• Drug: mirtazapinePMID
- Selective serotonin reuptake inhibitors and quality of life: a meta-analysis of randomized placebo-controlled trials — International Clinical Psychopharmacology (2025)• Drug: paroxetinePMID
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis — Translational Psychiatry (2025)• Drug: suvorexantOpen accessDOIPMIDPMCID
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis — Translational Psychiatry (2025)• Drug: lemborexantOpen accessDOIPMIDPMCID
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis — Translational Psychiatry (2025)• Drug: daridorexantOpen accessDOIPMIDPMCID
- Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis — Journal of Affective Disorders (2025)• Drug: propranololDOI
- Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)• Drug: gabapentin-enacarbilDOI
- Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)• Drug: pramipexoleDOI
- Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)• Drug: ropiniroleDOI
- An Evaluation of the Subcutaneous Depot Release of TV-46000, A Novel Long-Acting Injectable (LAI) Formulation of Risperidone, Under Extreme Conditions in Dogs, Minipigs and Humans — Pharmaceutics (2025)• Drug: risperidone-uzedyOpen accessDOIPMIDPMCID
- Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia — Expert Opinion on Drug Metabolism & Toxicology (2025)• Drug: aripiprazole-asimtufiiDOIPMID
- Sustained-release naltrexone for opioid dependence — Cochrane Database of Systematic Reviews (2025)• Drug: naltrexone-extended-releaseDOIPMID
- Low-dose amitriptyline versus cognitive behavioral therapy for insomnia in patients with medical comorbidity: results of a randomized controlled multicenter non-inferiority trial — Sleep (2025)• Drug: amitriptylinePMID
- Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose-response meta-analysis — Translational Psychiatry (2025)• Drug: amitriptylinePMID
- Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis — The British Journal of Psychiatry (2025)• Drug: amitriptylinePMID
- Assessing the metabolic impact of aripiprazole versus risperidone in the treatment of schizophrenia: a randomized double-blind controlled clinical trial — BMC Psychiatry (2025)• Drug: aripiprazoleOpen accessPMID
- Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD) — Journal of Affective Disorders (2025)• Drug: aripiprazolePMID
- The behavioural effects of the serotonin 1A receptor agonist buspirone on cognition and emotional processing in healthy volunteers — Psychopharmacology (2025)• Drug: buspironePMID
- Integrative systematic review on pharmacological, psychotherapeutic, and neurostimulatory treatment options in treatment-resistant anxiety disorders — Psychotherapy and Psychosomatics (2025)• Drug: buspironePMID
- Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis — The British Journal of Psychiatry (2025)• Drug: desipraminePMID